Cencora, Inc 8-K, filed Aug 18, 2021
Cencora, Inc. (COR)
8-K
2021-08-18
For: 2021-08-12
View Original
Added on
April 10, 2026
About this 8-K
Cencora, Inc filed this 8-K on August 18, 2021, reporting on events of August 12, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________________________
FORM 8-K
_________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2021
_________________________________
(Exact name of registrant as specified in its charter)
_________________________________
Commission File Number: 1-6671
| (State or other jurisdiction of | (I.R.S. Employer | |||||||||||||
| incorporation or organization) | Identification No.) | |||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(610 ) 727-7000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | |||||||||
| (NYSE) | |||||||||||
_________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On August 18, 2021, AmerisourceBergen Corporation (the “Company”) issued a press release stating that Executive Vice President and Chief Legal Officer John G. Chou has notified the Company of his plans to retire after a 19-year career with the Company. Effective September 1, 2021, Mr. Chou will be succeeded by Elizabeth S. Campbell, currently Senior Vice President and Deputy General Counsel, who will become Executive Vice President and Chief Legal Officer and a member of the Company’s Executive Management Committee. Mr. Chou will remain with the Company as Executive Vice President and Special Advisor to the Chairman & CEO until his retirement in fiscal 2022 to assist with the integration of the Alliance Healthcare businesses acquired in June 2021.
The press release is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description of Exhibit | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERISOURCEBERGEN CORPORATION | |||||||||||
| Date: | August 18, 2021 | By: | /s/ John G. Chou | ||||||||
| Name: | John G. Chou | ||||||||||
| Title: | Executive Vice President and Chief Legal Officer | ||||||||||
Exhibit 99.1
AmerisourceBergen Appoints Elizabeth Campbell to Executive Vice President and Chief Legal Officer
John Chou, current Executive Vice President and Chief Legal Officer, to retire after nearly 20 years of service
CONSHOHOCKEN, PA (August 18, 2021) – AmerisourceBergen, a global healthcare leader, announced the appointment of Elizabeth Campbell as Executive Vice President and Chief Legal Officer. Ms. Campbell will report directly to Steven H. Collis, Chairman, President and Chief Executive Officer, and will succeed John Chou, who has decided to retire after nearly 20 years of leading AmerisourceBergen’s legal function. As part of a planned transition, Mr. Chou will assume the role of Executive Vice President and Special Advisor to the Chairman & CEO where he will work closely to oversee the completion of post-closing negotiations and integration with Alliance Healthcare through the first part of calendar 2022.
“AmerisourceBergen has benefited from John’s leadership and lasting contributions to the organization,” said Collis. “I am personally and professionally grateful for John’s integrity, innovation and fierce intellect, which he displayed for more than two decades while always keeping our team members, customers and the patients we ultimately serve at the forefront.”
“As we continue to advance our company to provide innovation and global healthcare solutions, I am thrilled to welcome Elizabeth to our executive management team. She is a proven advisor with exceptional legal leadership and expertise and an in-depth knowledge of our business and industry,” Collis continued. “Elizabeth’s unmatched track record and legal execution make her an exceptional leader who will help AmerisourceBergen deliver long-term value for all its stakeholders as a leading global healthcare provider.”
In her new role, Ms. Campbell will oversee all legal and regulatory teams at AmerisourceBergen, and will serve as the primary legal advisor for senior management and the Board of Directors. Ms. Campbell has more than 11 years of experience at AmerisourceBergen, most recently as Deputy General Counsel, where she oversaw the legal teams that support all of AmerisourceBergen’s businesses and corporate, litigation, labor and employment, and intellectual property matters. Previously, Campbell worked as an attorney in a private practice in Philadelphia and Pittsburgh for more than 10 years. Ms. Campbell holds a Juris Doctor from the University of Pittsburgh.
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.